Compare KMDA & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | BIOA |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.3M | 481.0M |
| IPO Year | 2013 | 2024 |
| Metric | KMDA | BIOA |
|---|---|---|
| Price | $8.22 | $6.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.50 | ★ $35.63 |
| AVG Volume (30 Days) | 125.8K | ★ 563.8K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.96% | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $12.63 | $106.14 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $5.05 |
| 52 Week High | $9.35 | $25.96 |
| Indicator | KMDA | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 27.11 |
| Support Level | $7.91 | N/A |
| Resistance Level | $8.58 | $8.53 |
| Average True Range (ATR) | 0.22 | 0.43 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 23.71 | 0.00 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.